Managed Healthcare Executive6h
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Fiji scrambles to contain HIV outbreak driven by meth use and 'bluetoothing'
Fiji health authorities are scrambling to stem an outbreak of HIV, as growing meth use and alarming needle-sharing trends ...
Applied Clinical Trials Online4h
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
The Mail & Guardian14h
The endgame to HIV/Aids
The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...
STAT2d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
“Magic” for Those Who Can’t Take Pills: Groundbreaking HIV Treatment Achieves 98% Viral Suppression
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Immune response may be harnessed to control HIV, primary trial results suggest
Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...
STAT11h
HIV self-testing is easy, effective — and underutilized
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
Healio2d
Two more people potentially cured of HIV
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
Fierce Biotech3d
Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
GlobalData on MSN1d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
El Mundo on MSN1d
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...